Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Synthetic opioid, full mu-receptor agonist

Updated · Methodology

Mechanism

Both domperidone and methadone prolong the QT interval. Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish domperidone SmPC contraindicates such combinations because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation, and names methadone among them (AEMPS). QT prolongation and torsade de pointes have been reported during methadone treatment, especially at high doses: above 100 mg a day in the Spanish SmPC and above 200 mg a day in the US label. In laboratory studies, methadone inhibited cardiac potassium channels (methadone SmPC, AEMPS, and methadone label, US Food and Drug Administration, FDA). The documents do not say whether either drug changes the levels of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With methadone, QT prolongation has also been reported in people with no prior cardiac history who received high doses. In most people on the lower doses typically used for maintenance, concomitant medicines or conditions such as low potassium were contributing factors (methadone label, US Food and Drug Administration, FDA). The risk of arrhythmia is higher with low potassium, magnesium or calcium, high potassium, a slow heart rate, advanced or ischaemic heart disease and liver disease (domperidone and methadone SmPCs, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names methadone (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish methadone SmPCs do not name domperidone, but say to use methadone with caution in people at risk of QT prolongation, including those taking other QT-prolonging drugs (methadone SmPCs, AEMPS). The US label says to closely monitor heart rhythm during initiation and titration in people taking medicines that affect cardiac conduction (methadone label, US Food and Drug Administration, FDA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). For methadone, the Spanish SmPCs recommend an electrocardiogram (ECG) before treatment starts, two weeks after the start and before a dose increase (methadone SmPCs, AEMPS). If QT prolongation develops, the US label says to look for modifiable risk factors: concomitant medicines with cardiac effects, drugs that may cause electrolyte disturbances and drugs that may inhibit methadone metabolism (FDA). Withdraw methadone only gradually, because abrupt withdrawal can cause a withdrawal syndrome (methadone SmPC, AEMPS). Stop domperidone if signs of arrhythmia appear (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Methadone